SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)

Core Insights - SCYNEXIS, Inc. is set to present data on its second-generation antifungal drug candidate SCY-247 at the TIMM-12 Congress, highlighting its potential against drug-resistant Candida infections, particularly C. auris [1][2] Company Overview - SCYNEXIS, Inc. is a biotechnology company focused on developing innovative medicines to combat difficult-to-treat infections that are increasingly drug-resistant [7] - The company has developed a proprietary antifungal platform called "fungerps," with its first product, Ibrexafungerp, already approved for certain indications [8] Upcoming Presentations - The company will have six presentations at TIMM-12, showcasing SCY-247's efficacy against resistant Candida infections [2] - Key presentations include: - In vitro activity against C. auris, including strains with echinocandin-resistance mutations [3] - Uniform activity against various Candida species with no cross-resistance to echinocandins [5] - Efficacy in a murine model of C. auris infection, demonstrating significant reductions in fungal burden [6] Clinical Trials - SCYNEXIS anticipates reporting results from its Phase 1 Single Ascending Dose/Multiple Ascending Dose (SAD/MAD) trial for SCY-247 in Q3 2025, marking a significant step in the drug's development [4][9]